Synapse - Howard Scher

Results (1133)

Exploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Goodman, O. B.; Flaig, T. W.; Molina, A.; Mulders, P.; Suttmann, H.; Li, J.; Kheoh, T. S.; De Bono, J. S.; Scher, H. I.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Prostate-specific mRNA detection in whole blood as an analytically validated prognostic biomarker for patients with castration-resistant prostate cancer (CRPC)

Meeting Abstract

Danila, D. C.; Anand, A.; Heller, G.; Wan, M.; Herkal, A.; Patel, C.; Khanin, R.; Schultz, N.; Lilja, H.; Fleisher, M.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Risk assessment for severe hypocalcemia requiring hospitalization with denosumab

Meeting Abstract

Autio, K. A.; Farooki, A.; Glezerman, I.; Chan, A.; Barr, H. C.; Seyboth, B. M.; Schneider, C. W.; Heller, G.; Scher, H. I.; Morris, M. J.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Genomic heterogeneity of circulating tumor cells in castration-resistant prostate cancer (CRPC) revealed by single-cell sequencing

Meeting Abstract

Welsh, A.; Danila, D. C.; Anand, A.; Kendall, J.; Sawyers, C. L.; Fleisher, M.; Wigler, M.; Hicks, J. B.; Scher, H. I.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Chimeric antigen receptor (CAR(+)) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)

Meeting Abstract

Slovin, S. F.; Wang, X.; Hullings, M.; Arauz, G.; Bartido, S.; Lewis, J. S.; Schoder, H.; Zanzonico, P.; Scher, H. I.; Riviere, I.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Sera cytokine levels to predict survival in men with progressive castration-resistant prostate cancer

Meeting Abstract

Subudhi, S. K.; Heller, G.; Danila, D. C.; Anand, A.; Lacuna, K. P.; Samoila, A.; Fleisher, M.; Scher, H. I.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort

Meeting Abstract

Scher, H. I.; Smith, M. R.; Sweeney, C.; Corn, P. G.; Logothetis, C.; Vogelzang, N. J.; Smith, D. C.; Hussain, M.; George, D. J.; De Bono, J. S.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

A pilot study comparing circulation tumor cells (CTC) detection by AdnaTest prostate assay to CellSearch in patients (pts) with castration resistant prostate cancer (CRPC)

Meeting Abstract

Samoila, A.; Bastos, D. A.; Herkal, A.; Patel, C.; Curtis, K. R.; Schreiber, N. A.; Anand, A.; Fleisher, M.; Scher, H. I.; Danila, D. C.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302

Meeting Abstract

Ryan, C. J.; Londhe, A.; Molina, A.; Smith, M. R.; De Bono, J. S.; Mulders, P.; Rathkopf, D. E.; Saad, F.; Logothetis, C.; Fizazi, K.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302)

Meeting Abstract

Rathkopf, D. E.; Smith, M. R.; De Bono, J. S.; Logothetis, C.; Shore, N.; De Souza, P. L.; Fizazi, K.; Mulders, P.; Mainwaring, P. N.; Hainsworth, J. D.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save